[Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]
- PMID: 21592952
- DOI: 10.1556/OH.2011.29138
[Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]
Abstract
The therapy of rheumatoid arthritis has been changed by biological treatments. Their efficacy was evaluated in several randomized controlled trials. These trials were different in patient characteristics and the administration regimen. Placebo was the control and direct comparison of biological treatments is missing.
Objectives: In the present study the efficacy of biological treatments in patients with rheumatoid arthritis was compared based on the randomized controlled trials available in the literature. A meta-analysis was conducted and meta-regression was used to explore the relationship between disease characteristic variables and observed efficacy.
Results: The related scientific literature is broad. Thirty two trials involving 18,500 patients were included into the current meta-analysis. The relative odds ratios of biological treatments compared to placebo varied between 3.6 and 20.0, and between 6.4 and 35.5 in case of monotherapy and combination with non-biological therapy, respectively. Disease duration and added non-biological therapy were in positive relationship with relative efficacy. More severe disease resulted smaller relative effect.
Conclusions: The results show that the efficacy of biological treatments is similar. The relative efficacy worsens with more severe disease and improves with disease duration.
Similar articles
-
Radiological outcomes in randomized controlled trials on biologic therapies for rheumatoid arthritis: a narrative review.Clin Rheumatol. 2014 Jul;33(7):877-84. doi: 10.1007/s10067-014-2504-7. Epub 2014 Feb 8. Clin Rheumatol. 2014. PMID: 24510026 Review.
-
Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials.Asian Pac J Cancer Prev. 2014;15(8):3403-10. doi: 10.7314/apjcp.2014.15.8.3403. Asian Pac J Cancer Prev. 2014. PMID: 24870729
-
Immunotherapies in rheumatologic disorders.Med Clin North Am. 2012 May;96(3):475-96, ix-x. doi: 10.1016/j.mcna.2012.04.003. Epub 2012 May 1. Med Clin North Am. 2012. PMID: 22703852 Review.
-
Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.BioDrugs. 2014 Apr;28 Suppl 1:S25-37. doi: 10.1007/s40259-013-0065-y. BioDrugs. 2014. PMID: 24687236 Review.
-
The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials.Am J Med. 2014 Dec;127(12):1208-32. doi: 10.1016/j.amjmed.2014.06.012. Epub 2014 Jun 17. Am J Med. 2014. PMID: 24950486
Cited by
-
Characteristics and knowledge synthesis approach for 456 network meta-analyses: a scoping review.BMC Med. 2017 Jan 5;15(1):3. doi: 10.1186/s12916-016-0764-6. BMC Med. 2017. PMID: 28052774 Free PMC article.
-
Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison.Eur J Health Econ. 2014 May;15 Suppl 1(Suppl 1):S53-64. doi: 10.1007/s10198-014-0594-4. Epub 2014 May 16. Eur J Health Econ. 2014. PMID: 24832836 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical